查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1949485

聚乙二醇化蛋白市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、蛋白質類型、應用、最終用途、地區及競爭格局分類，2021-2031年）

PEGylated Proteins Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Consumable, Services), By Protein Type, By Application, By End-Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球聚乙二醇化蛋白質市場預計將從 2025 年的 10.5135 億美元大幅成長至 2031 年的 18.5463 億美元，複合年成長率為 9.92%。

這些治療性分子透過共用連接聚乙二醇（PEG）聚合物鏈進行修飾。該過程旨在改善其動態尺寸、增強其穩定性並延長其循環半衰期。推動市場成長的關鍵因素包括癌症和腎臟病等慢性疾病的日益普遍（這些疾病需要長效生物製劑治療），以及對能夠透過減少給藥頻率治療方法的需求不斷成長。此外，位點特異性偶聯技術的不斷改進正在促進開發出更均一、更有效的藥物，從而進一步推動該產業的發展。

市場概覽
預測期 2027-2031
市場規模：2025年 10.5135億美元
市場規模：2031年 18.5463億美元
複合年成長率：2026-2031年 9.92%
成長最快的細分市場 服務
最大的市場 北美洲

然而，由於產品開發和生產需要高額資本投入，市場面臨許多障礙。聚乙二醇化涉及複雜的化學過程，需要專門的純化系統來去除異構體和副產物，這增加了生產成本，並可能成為市場准入的障礙。根據歐洲製藥工業協會聯合會（EFPIA）的報告，到2024年，歐洲以研發為基礎的製藥業將在研發方面投入約550億歐元。這一數字凸顯了將包括聚乙二醇化蛋白在內的複雜生物製藥商業化所需的巨大資金負擔。這一高昂的成本障礙限制了中小企業的進入，並對全球範圍內的定價策略產生了影響。

市場促進因素

全球慢性疾病發生率的不斷上升，尤其是在腫瘤和免疫領域，是推動聚乙二醇化蛋白質療法應用的主要因素。這些修飾後的生物製藥對於長期維持治療濃度至關重要，從而減少了長期疾病管理所需的給藥頻率。根據美國癌症協會2024年1月發布的《2024年癌症事實與數據》，預計美國新增癌症病例數將首次超過200萬例。日益成長的疾病負擔凸顯了持續開發穩定、長效的蛋白質藥物的迫切需求，這些藥物能夠有效靶向腫瘤，同時最大限度地降低全身毒性，從而將聚乙二醇化技術的臨床效用與需要持續治療的患者數量不斷成長的需求直接聯繫起來。

與此需求同步，研發投入大幅增加，以拓展生技改良藥和新型生物製藥的研發管線。製藥公司正大力投資蛋白質工程，以克服未經修飾的生物製藥的局限性，例如腎臟清除率高和免疫抗原性強。例如，羅氏公司於2024年2月發布的2023年度報告顯示，該公司已投資132億瑞士法郎用於研發，以推進其產品組合，其中包括複雜的生物製藥。這項巨額投資正在推動偶聯技術的進步和下一代治療藥物的合成。此外，已上市的聚乙二醇化產品的商業性成功也持續驗證了這些策略的有效性。 2024年，優時比公司報告稱，其聚乙二醇化抗體片段藥物Cimzia在上年度實現了20.9億歐元的淨銷售額，展現了該類藥物巨大的盈利潛力，這將持續激發業界對該類藥物的興趣。

市場挑戰

產品研發生產所需的高額資本投入，對全球聚乙二醇化蛋白市場的成長構成了重大障礙。聚乙二醇化過程中複雜的化學反應，包括位點特異性偶聯和異構體去除，需要精密的純化設備，而這些設備的建造和維護成本極為高。這種經濟負擔使得市場參與者主要局限於大型製藥企業，實際上將那些本可推動創新的小型生物技術公司排除在外。因此，有限的市場參與降低了競爭壓力，維持了高昂的藥品價格，限制了對成本敏感地區的患者獲得這些先進療法的機會。

這種封閉的環境直接阻礙了新型生物製藥的研發。根據可及藥品協會（AAM）2025年的數據，高昂的研發成本和市場進入障礙造成了產業內巨大的缺口，在118種具有競爭力的生物製藥中，僅有12種以生物相似藥的形式進行研發。這項數據凸顯了開發複雜生物製藥（例如聚乙二醇化蛋白）所面臨的財務障礙如何阻礙了更多治療方案的商業化，最終限制了整體市場的擴張。

市場趨勢

聚乙二醇化療法在眼科領域的拓展標誌著其應用範圍從傳統的血液學和腫瘤學領域中發生了變革性轉變。製藥公司正利用聚乙二醇化技術延長用於治療地圖狀萎縮的補體抑制劑的玻璃體內半衰期，這一顯著改進減少了侵入性玻璃體內注射的頻率，並提高了患者的依從性。該應用在眼科這一專業領域正迅速展現出商業性可行性。例如，Apellis Pharmaceuticals在2025年2月發布的「2024年第四季及全年業績」報告中指出，其聚乙二醇化療法Syfovre的2024年全年淨產品銷售額為6.119億美元，凸顯了其在眼科領域的強大市場滲透率。

同時，業界也擴大在抗體藥物複合體（ADC）中使用聚乙二醇（PEG）連接子，以提高其穩定性和治療指數。在這些複雜的分子中，PEG間隔基通常被引入連接子系統中，以掩蓋細胞毒性有效載荷的疏水性，從而提高溶解度並防止循環過程中的聚集。這種結構最佳化使得抗體藥物比（DDA）得以最佳化，從而使含PEG的偶聯物在腫瘤藥物研發管線中具有重要價值。根據Astra Zeneca於2025年2月發布的“2024會計年度全年及第四季度財務業績”，採用PEG連接子技術的ADC藥物Enhertu的全球銷售額預計將在2024年達到37.54億美元，這表明先進的PEG化技術在下一代生物製藥中發揮著重要作用。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球聚乙二醇化蛋白市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品分類（耗材（聚乙二醇化試劑盒及試劑（單功能鎖狀聚乙二醇、雙功能聚乙二醇等））、聚乙二醇化試劑盒）、服務）
    • 依蛋白質類型（集落刺激因子、干擾素、促紅血球生成素、單株抗體、重組因子VII、其他）
    • 依應用領域（癌症治療、肝炎、慢性腎臟病、血友病、多發性硬化症、消化系統疾病等）
    • 依最終用途（製藥公司、生物技術公司、合約研究組織和學術研究機構、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美聚乙二醇化蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲聚乙二醇化蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區聚乙二醇化蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲聚乙二醇化蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲聚乙二醇化蛋白市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球聚乙二醇化蛋白市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Celares GmbH
  • Quanta BioDesign, Ltd
  • Biomatrik Inc
  • Laysan Bio Inc.
  • Iris Biotech GMBH
  • Valley Proteins, Inc.
  • Enzon Pharmaceuticals, Inc
  • Takeda Pharmaceuticals Company Limited

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24049

The Global PEGylated Proteins Market is projected to expand considerably, growing from USD 1051.35 Million in 2025 to USD 1854.63 Million by 2031, reflecting a CAGR of 9.92%. These therapeutic molecules are modified via the covalent attachment of polyethylene glycol polymer chains, a process intended to enhance hydrodynamic size, bolster stability, and prolong circulation half-life. Key factors propelling market growth include the escalating prevalence of chronic conditions like cancer and kidney disorders, which require long-acting biologic treatments, and the rising demand for therapies that improve patient compliance by reducing dosing frequency. Furthermore, ongoing improvements in site-specific conjugation technologies are facilitating the creation of more uniform and potent drug products, thereby strengthening industry development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1051.35 Million
Market Size 2031USD 1854.63 Million
CAGR 2026-20319.92%
Fastest Growing SegmentServices
Largest MarketNorth America

Conversely, the market encounters substantial obstacles due to the high capital intensity essential for product development and manufacturing. The intricate chemical procedures involved in PEGylation require specialized purification systems to eliminate isomers and byproducts, resulting in elevated production costs that can restrict market accessibility. As reported by the European Federation of Pharmaceutical Industries and Associations (EFPIA), the research-based pharmaceutical sector in Europe invested approximately €55,000 million in R&D in 2024, a figure that highlights the immense financial commitment needed to bring complex biologics, including PEGylated proteins, to the commercial landscape. This significant cost barrier limits the entry of smaller organizations and influences pricing strategies on a global scale.

Market Driver

The increasing global incidence of chronic diseases, particularly within the fields of oncology and immunology, acts as a primary catalyst for the adoption of PEGylated protein therapeutics. These modified biologics are critical for sustaining therapeutic concentrations over prolonged periods, thereby lowering the administration frequency needed for long-term disease management. According to the American Cancer Society's 'Cancer Facts & Figures 2024', released in January 2024, the number of new cancer cases in the United States was projected to exceed 2 million for the first time. This rising disease burden underscores the urgent necessity for the continued development of stable, long-acting protein drugs capable of effectively targeting tumors while minimizing systemic toxicity, directly linking the clinical utility of PEGylation to the growing patient population requiring sustained intervention.

Parallel to this demand is a massive surge in research and development expenditures aimed at broadening the pipeline of biobetters and novel biologics. Pharmaceutical companies are investing heavily in protein engineering to address the limitations of unmodified biologics, such as rapid renal clearance and immunogenicity. For instance, Roche's 'Annual Report 2023', published in February 2024, noted a CHF 13.2 billion investment in research and development to advance its portfolio, including complex biologic formulations. Such significant financial commitments facilitate the refinement of conjugation technologies and the synthesis of next-generation therapeutics. Moreover, the commercial success of established PEGylated products continues to validate these strategies; UCB reported in 2024 that net sales for their PEGylated antibody fragment Cimzia reached €2.09 billion during the previous fiscal year, demonstrating the high revenue potential that drives ongoing industrial focus on this drug class.

Market Challenge

The significant capital intensity required for product development and manufacturing presents a major hurdle to the growth of the Global PEGylated Proteins Market. The complex chemical processes inherent to PEGylation, such as site-specific conjugation and isomer removal, demand advanced purification infrastructures that are prohibitively expensive to establish and sustain. This financial burden restricts market entry primarily to large pharmaceutical conglomerates with substantial resources, effectively excluding smaller biotechnology firms that might otherwise drive innovation. Consequently, the limited number of participants leads to reduced competitive pressure, which maintains high drug prices and restricts patient access to these advanced therapies in cost-sensitive regions.

This exclusionary environment directly suppresses the pipeline of new biologic products. According to the Association for Accessible Medicines in 2025, high development costs and market barriers have created a significant void in the industry, where only 12 molecules had biosimilars in development out of 118 biologics eligible for competition. This statistic emphasizes how the financial threshold for developing complex biologics, such as PEGylated proteins, prevents a broader range of therapeutic options from reaching the commercial stage, thereby dampening overall market expansion.

Market Trends

The extension of PEGylated therapeutics into ophthalmic indications marks a transformative shift, expanding beyond traditional hematological and oncological applications. Pharmaceutical developers are utilizing PEGylation to prolong the vitreous half-life of complement inhibitors used to treat geographic atrophy, a critical modification that reduces the frequency of invasive intravitreal injections and improves patient adherence. This specific application has rapidly proven its commercial viability within the specialized eye care segment. For example, Apellis Pharmaceuticals reported in its 'Fourth Quarter and Full Year 2024 Financial Results' in February 2025 that full-year 2024 net product revenue for its PEGylated therapy Syfovre totaled $611.9 million, highlighting robust market uptake in the ophthalmology sector.

Simultaneously, the industry is seeing increased utilization of PEG linkers in antibody-drug conjugates (ADCs) to enhance stability and the therapeutic index. In these complex molecules, PEG spacers are frequently integrated into linker systems to mask the hydrophobicity of cytotoxic payloads, improving solubility and preventing aggregation during circulation. This structural refinement allows for optimized drug-to-antibody ratios, driving substantial value for PEG-containing conjugates in the oncology pipeline. According to AstraZeneca's 'Full Year and Q4 2024 Results' from February 2025, combined global sales for the PEG-linker-enabled ADC Enhertu reached $3,754 million in 2024, validating the essential role of advanced PEGylation technologies in next-generation biologics.

Key Market Players

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Celares GmbH
  • Quanta BioDesign, Ltd
  • Biomatrik Inc
  • Laysan Bio Inc.
  • Iris Biotech GMBH
  • Valley Proteins, Inc.
  • Enzon Pharmaceuticals, Inc
  • Takeda Pharmaceuticals Company Limited

Report Scope

In this report, the Global PEGylated Proteins Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

PEGylated Proteins Market, By Product

  • Consumable (PEGylation Kits and Reagents (Monofunctional Linear PEGs, Bifunctional PEGs, others), PEGylation Kits)
  • Services

PEGylated Proteins Market, By Protein Type

  • Colony Stimulating Factors
  • Interferons
  • Erythropoietin
  • mAbs
  • Recombinant Factor VII
  • Others

PEGylated Proteins Market, By Application

  • Cancer Treatment
  • Hepatitis
  • Chronic Kidney Diseases
  • Hemophilia
  • Multiple Sclerosis
  • Gastrointestinal Disorders
  • Others

PEGylated Proteins Market, By End-Use

  • Pharmaceuticals
  • Biotechnology Companies
  • CROs and Academic Research Institutes
  • Others

PEGylated Proteins Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PEGylated Proteins Market.

Available Customizations:

Global PEGylated Proteins Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global PEGylated Proteins Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Consumable (PEGylation Kits and Reagents (Monofunctional Linear PEGs, Bifunctional PEGs, others), PEGylation Kits), Services)
    • 5.2.2. By Protein Type (Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VII, Others)
    • 5.2.3. By Application (Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders, Others)
    • 5.2.4. By End-Use (Pharmaceuticals, Biotechnology Companies, CROs and Academic Research Institutes, others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2025)
  • 5.3. Market Map

6. North America PEGylated Proteins Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Protein Type
    • 6.2.3. By Application
    • 6.2.4. By End-Use
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States PEGylated Proteins Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Protein Type
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End-Use
    • 6.3.2. Canada PEGylated Proteins Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Protein Type
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End-Use
    • 6.3.3. Mexico PEGylated Proteins Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Protein Type
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End-Use

7. Europe PEGylated Proteins Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Protein Type
    • 7.2.3. By Application
    • 7.2.4. By End-Use
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany PEGylated Proteins Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Protein Type
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End-Use
    • 7.3.2. France PEGylated Proteins Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Protein Type
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End-Use
    • 7.3.3. United Kingdom PEGylated Proteins Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Protein Type
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End-Use
    • 7.3.4. Italy PEGylated Proteins Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Protein Type
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End-Use
    • 7.3.5. Spain PEGylated Proteins Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Protein Type
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End-Use

8. Asia Pacific PEGylated Proteins Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Protein Type
    • 8.2.3. By Application
    • 8.2.4. By End-Use
    • 8.2.5. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China PEGylated Proteins Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Protein Type
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End-Use
    • 8.3.2. India PEGylated Proteins Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Protein Type
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End-Use
    • 8.3.3. Japan PEGylated Proteins Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Protein Type
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End-Use
    • 8.3.4. South Korea PEGylated Proteins Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Protein Type
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End-Use
    • 8.3.5. Australia PEGylated Proteins Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Protein Type
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End-Use

9. Middle East & Africa PEGylated Proteins Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Protein Type
    • 9.2.3. By Application
    • 9.2.4. By End-Use
    • 9.2.5. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia PEGylated Proteins Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Protein Type
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End-Use
    • 9.3.2. UAE PEGylated Proteins Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Protein Type
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End-Use
    • 9.3.3. South Africa PEGylated Proteins Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Protein Type
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End-Use

10. South America PEGylated Proteins Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Protein Type
    • 10.2.3. By Application
    • 10.2.4. By End-Use
    • 10.2.5. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil PEGylated Proteins Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Protein Type
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End-Use
    • 10.3.2. Colombia PEGylated Proteins Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Protein Type
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End-Use
    • 10.3.3. Argentina PEGylated Proteins Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Protein Type
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End-Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global PEGylated Proteins Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Merck KGaA
  • 15.3. Celares GmbH
  • 15.4. Quanta BioDesign, Ltd
  • 15.5. Biomatrik Inc
  • 15.6. Laysan Bio Inc.
  • 15.7. Iris Biotech GMBH
  • 15.8. Valley Proteins, Inc.
  • 15.9. Enzon Pharmaceuticals, Inc
  • 15.10. Takeda Pharmaceuticals Company Limited

16. Strategic Recommendations

17. About Us & Disclaimer